Results and impact (M1-M18)
Within the first 18 months we achieved the following results and impact by objective:
1) we completed the geospatial, ethical, and lab preparatory work, enabling initiation of the clinical studies. Notably we have completed an census studies in both Ethiopia and Madagascar, and completed the necessary preparations for sample collection in the baseline study. With the PvSeroTAT intervention that we will trial, we expect impact on reducing disease burden on patients (with associated improved quality of life, healthcare savings and increased productivity) and enabling health care providers to better tackle and manage malaria. The PvSTATEM clinical trial will also provide evidence for use case of P. vivax serological diagnostics as specified in the WHO Preferred Product Characteristics (PPC) for diagnosis of P. vivax malaria relapses.
2) we obtained insights on understandings of malaria and other nosological entities; practices associated with their diagnoses, treatment, and prevention; and expectations of upcoming clinical trials. These activities had both societal impact, in that they engaged local communities and individuals, and economic impact because the project hired local field assisants.
3) We used the collective intelligence data to inform an mHealth strategy, and we built an early version of the digital tool, with societal impact (local stakeholders providing their reflections, digital tool extending the reach of safe radical cure) and economic impact (simplified deployment to increase employability, digital tool development in Africa for an anticipated effect in the same region).
1, 2, 4*) we hired students from several consortium partners, including those in Ethiopia, Madagascar, and EU countries, and strengthened their research capacities.
*new objective since month 12
